Table 1. Epidemiological and clinical characteristics of multiple sclerosis patients included in the study.
| Inflammatory MS/ RR-MS | Progressive MS | |||||||
|---|---|---|---|---|---|---|---|---|
| Characteristics | CD-MS | RR-MS Remission | RR-MS Active | RELAPSES | RESPONDERS | NON RESPONDERS | SP-MS | PP-MS |
| No. of patients a | 129 | 23 | 13 | 11 | 20 | 13 | 31 | 18 |
| Gender F/M a | 85/44 | 17/6 | 8/5 | 8/3 | 10/10 | 11/2 | 22/9 | 9/9 |
| Age (years) b | 42 (33–53) | 38 (32–46) | 29 (26–37) | 30 (26–42) | 37 (33–41) | 38 (29–43) | 53 (46–58) | 58 (45–64) |
| Disease duration (yrs) b | 11 (3–17.5) | 9 (5–16) | 1 (1–4.5) | 1 (0–9) | 9 (1.8–16.3) | 11 (5–15.5) | 19 (13–27) | 20.5 (8.8–26.3) |
| Age at onset (yrs) b | 28 (24–36) | 28 (22–32) | 26 (25–35) | 28 (25–40) | 26 (23–35) | 26 (24–38) | 32 (26–41) | 40 (33–50) |
| EDSS b | 2.5 (1.0–5.5) | 0.0 (0.0–1.5) | 2.5 (1.0–3.0) | 3.0 (2.0–4.0) | 1.0 (0.0–2.0) | 3.5 (2.3–4.5) | 8.0 (7.5–8.5) | 8.0 (7.3–8.0) |
| Progression Index c | 0.3 (0.1–0.6) | 0.0 (0.0–0.1) | 1.5 (0.2–2.9) | 0.8 (0.2–5.4) | 0.1 (0.0–0.3) | 0.3 (0.2–0.5) | 0.4 (0.3–0.6) | 0.4 (0.3–0.9) |
| No. of relapses d | ||||||||
| 0 | 73 | 17 | 0 | 6 | 2 | 0 | 30 | 18 |
| 1 | 18 | 4 | 3 | 3 | 4 | 3 | 1 | 0 |
| 2–5 | 38 | 2 | 10 | 2 | 14 | 10 | 0 | 0 |
| Treatment, IFNβ a | 20 | _ | _ | _ | 20 | _ | _ | _ |
| Treatment duration (mo) b | 18 (6–24) | _ | _ | _ | 18 (6–24) | _ | _ | _ |
CD-MS clinically definite MS group, RR-MS Remission: relapsing remitting MS in remission, RR-MS Active: relapsing remitting MS with active disease, RESPONDERS: RR-MS under treatment with IFNβ, NON-RESPONDERS: relapsing remitting MS that did not respond to Interferon-β, SP-MS: secondary progressive MS, PP-MS: primary progressive MS.
EDSS expanded disability status scale, IFNβ: interferon-β.
a Number of patients;
b Median (25th-75th percentiles)
c EDSS/Disease duration (years);
d Number of relapses during preceding 2 years.